Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity.
Gillespie
E
E
Preclinical Cardiovascular Research Bristol-Myers Company, Wallingford, CT 06492-7660.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D001792:Blood Platelets / Q000201:enzymology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D020105:Milrinone; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011728:Pyridones / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology*; D013806:Theophylline / Q000494:pharmacology
D010975:Platelet Aggregation Inhibitors; D011728:Pyridones; D011799:Quinazolines; D013806:Theophylline; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D020105:Milrinone; C021139:anagrelide; D015056:1-Methyl-3-isobutylxanthine